The latest price target for Grace Therapeutics (NASDAQ:GRCE) was reported by HC Wainwright & Co. on February 18, 2025. The analyst firm set a price target for $12.00 expecting GRCE to rise to within 12 months (a possible 450.46% upside). 1 analyst firms have reported ratings in the last year.

The latest analyst rating for Grace Therapeutics (NASDAQ:GRCE) was provided by HC Wainwright & Co., and Grace Therapeutics reiterated their buy rating.

There is no last upgrade for Grace Therapeutics

There is no last downgrade for Grace Therapeutics.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Grace Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Grace Therapeutics was filed on February 18, 2025 so you should expect the next rating to be made available sometime around February 18, 2026.

While ratings are subjective and will change, the latest Grace Therapeutics (GRCE) rating was a reiterated with a price target of $12.00 to $12.00. The current price Grace Therapeutics (GRCE) is trading at is $2.18, which is out of the analyst’s predicted range.